Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

obecabtagene autoleucel

View Patient Information
A preparation of autologous T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AUTO1 CAR-T cells
autologous anti-CD19 CAR T cells AUTO1
autologous anti-CD19 chimeric antigen receptor T lymphocytes AUTO1
autologous CD19-targeted CAR T cells AUTO1
CD19CAR T cells AUTO1
CD19CAT-41BBZ CAR T cells AUTO1
obe-cel
US brand name:Aucatzyl
Code name:AUTO 1
AUTO-1
AUTO1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search